Tahrat Halima, Munir Ali, Marchetti Federico
GSK, Rockville, MD, USA.
GSK, Wavre, Belgium.
Hum Vaccin Immunother. 2025 Dec;21(1):2442780. doi: 10.1080/21645515.2024.2442780. Epub 2025 Jan 3.
Rotavirus, a leading cause of severe acute gastroenteritis in children, is largely preventable through immunization with two internationally licensed oral rotavirus vaccines (RVVs) included in national programs across over 100 countries. These RVVs are administered in either two (Rotarix™; 2D-RV) or three (RotaTeq®; 3D-RV) doses. We aimed to assess the global coverage, completion, and compliance of 2D-RV and 3D-RV in various settings, and to identify factors influencing vaccine coverage. We conducted a systematic review of PubMed and Embase for articles published between 2006 and 2021. We included 74 publications across 31 countries. RVV coverage rates and the factors associated with coverage varied widely among countries based on income level, RVV used, and the year of vaccination. Due to market bias and insufficient studies, valid RVVs coverage comparisons couldn't be made. However, 2D-RV had better completion/compliance rates than 3D-RV in Italy, Mexico, and the US.
轮状病毒是导致儿童严重急性胃肠炎的主要病因,通过接种两种国际许可的口服轮状病毒疫苗(RVV)在很大程度上是可以预防的,这两种疫苗已被纳入100多个国家的国家计划。这些RVV以两剂(Rotarix™;2D-RV)或三剂(RotaTeq®;3D-RV)的方式接种。我们旨在评估2D-RV和3D-RV在不同环境中的全球覆盖率、完成率和依从性,并确定影响疫苗覆盖率的因素。我们对2006年至2021年期间发表在PubMed和Embase上的文章进行了系统综述。我们纳入了来自31个国家的74篇出版物。基于收入水平、使用的RVV和接种年份,各国的RVV覆盖率以及与覆盖率相关的因素差异很大。由于市场偏差和研究不足,无法进行有效的RVV覆盖率比较。然而,在意大利、墨西哥和美国,2D-RV的完成率/依从率高于3D-RV。